Cost of Grants are on the Move
Applied Clinical Trials
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials. While the relative cost of conducting a clinical trial in a specific geography is not the sole driver in the decision of where to place study sites, relative costs do play a role.
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials. While the relative cost of conducting a clinical trial in a specific geography is not the sole driver in the decision of where to place study sites, relative costs do play a role.
Each year, TTC reports on the relative costs of clinical grants around the world, drawing upon data in the GrantPlan database. Subscribers to this database conduct over 76% of all the commercial clinical trials.
Patient Costs in Phase II-III Trials
The data show that the United States remains the most expensive country for clinical grants, followed by the United Kingdom. Newer geographies for clinical research such as Eastern Europe, Latin America, and Asia are distinctly less expensive.
However, clinical grant costs in these newer research areas are increasing more rapidly than in North America and Europe . The United States and Western Europe (excluding the UK) have been averaging 1% to 2% annual increases. In contrast, clinical grants in the new geographies are increasing at rates over 12%.—TTC (For more information, please contact help@ttc-ilc.com)
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
